DE69229254T2 - Verfahren zur Herstellung von menschlichen Lymphozyten und menschlichen Antikörpern; und so hergestellte Antikörper - Google Patents

Verfahren zur Herstellung von menschlichen Lymphozyten und menschlichen Antikörpern; und so hergestellte Antikörper

Info

Publication number
DE69229254T2
DE69229254T2 DE69229254T DE69229254T DE69229254T2 DE 69229254 T2 DE69229254 T2 DE 69229254T2 DE 69229254 T DE69229254 T DE 69229254T DE 69229254 T DE69229254 T DE 69229254T DE 69229254 T2 DE69229254 T2 DE 69229254T2
Authority
DE
Germany
Prior art keywords
antibodies
human
processes
produced
production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69229254T
Other languages
English (en)
Other versions
DE69229254D1 (de
Inventor
Toshio Kudo
Shuichi Hiyamuta
Toshiyuki Tanedani
Akihiko Kadota
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Idemitsu Kosan Co Ltd
Original Assignee
Idemitsu Kosan Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP4244250A external-priority patent/JPH05304988A/ja
Application filed by Idemitsu Kosan Co Ltd filed Critical Idemitsu Kosan Co Ltd
Publication of DE69229254D1 publication Critical patent/DE69229254D1/de
Application granted granted Critical
Publication of DE69229254T2 publication Critical patent/DE69229254T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0271—Chimeric animals, e.g. comprising exogenous cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0381—Animal model for diseases of the hematopoietic system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
DE69229254T 1991-10-30 1992-10-29 Verfahren zur Herstellung von menschlichen Lymphozyten und menschlichen Antikörpern; und so hergestellte Antikörper Expired - Fee Related DE69229254T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP31166591 1991-10-30
JP7018792 1992-02-20
JP4244250A JPH05304988A (ja) 1992-02-20 1992-08-20 抗ｈｄモノクローナル抗体及びそれを産生する細胞株

Publications (2)

Publication Number Publication Date
DE69229254D1 DE69229254D1 (de) 1999-07-01
DE69229254T2 true DE69229254T2 (de) 1999-09-23

Family

ID=27300259

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69229254T Expired - Fee Related DE69229254T2 (de) 1991-10-30 1992-10-29 Verfahren zur Herstellung von menschlichen Lymphozyten und menschlichen Antikörpern; und so hergestellte Antikörper

Country Status (3)

Country Link
US (2) US5681729A (de)
EP (1) EP0539970B1 (de)
DE (1) DE69229254T2 (de)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5550020A (en) * 1994-07-08 1996-08-27 Visible Genetics Inc. Method, reagents and kit for diagnosis and targeted screening for retinoblastoma
US5783186A (en) * 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
AU9374198A (en) * 1997-09-08 1999-03-29 Idec Pharmaceuticals Corporation Methods for producing human antibodies in scid mice using dendritic cells
WO2000002584A2 (en) 1998-07-13 2000-01-20 Board Of Regents, The University Of Texas System Cancer treatment methods using antibodies to aminophospholipids
US8071072B2 (en) * 1999-10-08 2011-12-06 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US8048416B2 (en) 1999-10-08 2011-11-01 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US6657048B2 (en) * 1999-10-08 2003-12-02 Arius Research, Inc. Individualized anti-cancer antibodies
US7419792B2 (en) * 1999-10-08 2008-09-02 Arius Research Inc. Laminin Receptor 1 Precursor Protein (37LRP) epitope delineated by an Hepatocellular carcinoma specific antibody
US7252821B2 (en) * 1999-10-08 2007-08-07 Arius Research Inc. Cancerous disease modifying antibodies
US7442776B2 (en) * 1999-10-08 2008-10-28 Young David S F Cancerous disease modifying antibodies
US20040001789A1 (en) * 1999-10-08 2004-01-01 Young David S. F. Cytotoxicity mediation of cells evidencing surface expression of gp96 or precursors thereof
US6794494B1 (en) 2003-04-14 2004-09-21 Arius Research, Inc. Cancerous disease modifying antibodies
US20040105816A1 (en) * 1999-10-08 2004-06-03 Young David S. F. Cancerous disease modifying antibodies
US6180357B1 (en) * 1999-10-08 2001-01-30 Arius Research, Inc. Individualized patient-specific anti-cancer antibodies
US7189397B2 (en) * 1999-10-08 2007-03-13 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7947496B2 (en) * 1999-10-08 2011-05-24 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US20050100542A1 (en) * 1999-10-08 2005-05-12 Young David S. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7256271B2 (en) 2003-01-21 2007-08-14 Arius Research Inc. Cancerous disease modifying antibodies
US20080124327A1 (en) * 1999-10-08 2008-05-29 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US20090004103A1 (en) * 1999-10-08 2009-01-01 Young David S F Cytotoxicity mediation of cells evidencing surface expression of CD44
US7431923B2 (en) * 2005-01-03 2008-10-07 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
US7442777B2 (en) * 2000-11-29 2008-10-28 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
US7361343B2 (en) * 2003-01-21 2008-04-22 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
US20060210474A1 (en) * 2000-11-29 2006-09-21 Young David S Cytotoxicity mediation of cells evidencing surface expression of CD63
US7534429B2 (en) * 2000-11-29 2009-05-19 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
US7009040B2 (en) * 2003-01-21 2006-03-07 Arius Research, Inc. Cancerous disease modifying antibodies
US20040175378A1 (en) 2002-07-15 2004-09-09 Board Of Regents, The University Of Texas System Selected antibody compositions and methods for binding to aminophospholipids
NZ540669A (en) * 2002-11-19 2008-08-29 Clluone Diagnostics As Methods and kits for diagnosing and treating B-cell chronic lymphocytic leukemia (B-CLL)
US7361342B2 (en) * 2003-01-21 2008-04-22 Arius Research Inc. Cancerous disease modifying antibodies
US7468254B2 (en) * 2003-01-21 2008-12-23 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of MCSP
US7393531B2 (en) * 2003-01-21 2008-07-01 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of MCSP
US7488475B2 (en) 2003-01-21 2009-02-10 Arius Research, Inc. Antibody therapy of tumors
US7175846B2 (en) * 2003-01-21 2007-02-13 Arius Research Inc. Cancerous disease modifying antibodies
DE602004027992D1 (de) * 2003-02-19 2010-08-19 Novartis Ag In metastatischen menschlichen tumorzellen exprimiertes glycoproteinantigen sima135
BRPI0409383A (pt) * 2003-04-14 2006-04-18 Univ Texas métodos para produção livre de hibridoma ex vivo de anticorpos policlonais e monoclonais e geração de populações de célula imortalizada
US20080213169A1 (en) * 2003-04-14 2008-09-04 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of CD59
US7195764B2 (en) 2003-04-14 2007-03-27 Arius Research Inc. Cancerous disease modifying antibodies
US20060140963A1 (en) * 2003-04-14 2006-06-29 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of CD59
US7399835B2 (en) * 2004-02-26 2008-07-15 Arius Research Inc. Cancerous disease modifying antibodies
US20080025977A1 (en) * 2003-04-14 2008-01-31 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of CD59
US20050027106A1 (en) * 2003-07-28 2005-02-03 Young David S. F. Cancerous disease modifying antibodies
US7348413B2 (en) * 2004-02-26 2008-03-25 Arius Research Inc. Cancerous disease modifying antibodies
US20050255041A1 (en) * 2004-05-13 2005-11-17 Arius Research, Inc. Cancerous disease modifying antibodies
CA2521973C (en) * 2004-09-29 2013-12-10 Tir Systems Ltd. System and method for controlling luminaires
US7494648B2 (en) * 2005-08-02 2009-02-24 Hoffmann-La Roche Inc. Cancerous disease modifying antibodies
US7456258B2 (en) 2005-08-02 2008-11-25 Arius Research, Inc. Cancerous disease modifying antibodies
US7452978B2 (en) 2005-08-02 2008-11-18 Arius Research, Inc. Cancerous disease modifying antibodies
US7411046B2 (en) 2005-08-02 2008-08-12 Arius Research Inc Cancerous disease modifying antibodies
US7452979B2 (en) 2005-08-02 2008-11-18 Arius Research, Inc. Cancerous disease modifying antibodies
US7456259B2 (en) 2005-08-02 2008-11-25 Arius Research, Inc. Cancerous disease modifying antibodies
US20080305104A1 (en) * 2006-02-24 2008-12-11 Young David S F Cytotoxicity mediation of cells evidencing surface expression of TROP-2
EP1996699A4 (de) 2006-02-24 2009-02-25 Arius Res Inc Antikörper, die krebserkrankungen modifizieren
US7420041B2 (en) * 2006-02-24 2008-09-02 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2
US7485300B2 (en) 2006-02-24 2009-02-03 Arius Research Inc. Cancerous disease modifying antibodies
US20080213267A1 (en) * 2006-02-24 2008-09-04 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2
US20080089891A1 (en) * 2006-07-26 2008-04-17 Arius Research, Inc. Cancerous disease modifying antibodies
RU2009122233A (ru) * 2006-11-13 2010-12-20 Ф.Хоффманн-Ля Рош Аг (Ch) Антитела, модифицирующие раковые заболевания
EP2092058A1 (de) * 2006-11-13 2009-08-26 Arius Research Inc. Antikörper, die krebserkrankungen modifizieren
AU2007321664A1 (en) * 2006-11-13 2008-05-22 F. Hoffmann-La Roche Ag Cancerous disease modifying antibodies
US20080206133A1 (en) * 2007-01-23 2008-08-28 Young David S F Cancerous Disease Modifying Antibodies
US8003761B2 (en) 2007-01-23 2011-08-23 Hoffmann-La Roche Inc. Cancerous disease modifying antibodies
MX2009009919A (es) * 2007-03-26 2009-10-19 Hoffmann La Roche Anticuerpo 010207-01 modificador de la enfermedad del cancer, producido por la linea celular ar51a630.3 del hibridoma.
AU2008247285A1 (en) * 2007-05-07 2008-11-13 F. Hoffmann-La Roche Ag Cancerous disease modifying antibodies
US8715743B2 (en) 2007-08-03 2014-05-06 Musc Foundation For Research Development Human monoclonal antibodies and methods for producing the same
US20090191197A1 (en) * 2008-01-28 2009-07-30 Young David S F Cancerous disease modifying antibodies
WO2009124381A1 (en) * 2008-04-10 2009-10-15 F. Hoffmann-La Roche Ag An anti-cancer cytotoxic monoclonal antibody
EP2291406A4 (de) * 2008-05-19 2012-12-12 Takeda Pharmaceutical Zytotoxischer monoklonaler antikörper gegen krebs
JP2011528010A (ja) * 2008-07-17 2011-11-10 武田薬品工業株式会社 癌性疾患修飾抗体
WO2011004899A1 (en) 2009-07-06 2011-01-13 Takeda Pharmaceutical Company Limited Cancerous disease modifying antibodies
AU2010303737B2 (en) 2009-10-06 2014-05-29 Institute For Research In Biomedicine (Irb) Genetically modified mice and engraftment
RU2730643C2 (ru) 2011-02-15 2020-08-24 Ридженерон Фармасьютикалз, Инк. Гуманизированные m-csf мыши
NZ741951A (en) 2012-09-07 2020-04-24 Institute For Res In Biomedicine Irb Genetically modified non-human animals and methods of use thereof
CN114766432A (zh) 2012-11-05 2022-07-22 再生元制药公司 经遗传修饰的非人动物及其使用方法
CN106536546B (zh) 2014-05-19 2021-04-30 再生元制药公司 表达人epo的经遗传修饰的非人动物
AU2016247892B2 (en) 2015-04-13 2022-05-26 Institute For Research In Biomedicine (Irb) Humanized SIRPA-IL15 knockin mice and methods of use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5780327A (en) * 1980-11-05 1982-05-19 Toyobo Co Ltd Carcinostatic agent
ES2071620T3 (es) * 1987-12-23 1995-07-01 Univ Leland Stanford Junior Mamiferos inmunodeficientes quimericos y su utilizacion.
JPH01202295A (ja) * 1988-02-05 1989-08-15 Eisai Co Ltd 抗ｈｄモノクロナール抗体及びその製法
JPH01216267A (ja) * 1988-02-25 1989-08-30 Shinotesuto Kenkyusho:Kk Ｈｄ抗原の酵素免疫測定法
DK0438053T3 (da) * 1990-01-15 1999-11-22 Yeda Res & Dev Varig transplantation og udvikling af humane hæmopoietiske cellelinjer i normale pattedyr
JPH03240498A (ja) * 1990-02-16 1991-10-25 Nobuyoshi Shimizu 抗体およびそれを使用した免疫分析方法
CA2063408A1 (en) * 1990-05-03 1991-11-04 Susan Mayo Human lymphoid tissue in an immunocompromised host
EP0484512A4 (en) * 1990-05-25 1993-05-05 Systemix, Inc. Human peripheral blood cells in an immunocompromised host
WO1992001043A1 (fr) * 1990-07-10 1992-01-23 Nkk Corporation Hydridomes produisant une immunoglobuline g aviaire specifique
WO1993005796A1 (en) * 1991-09-19 1993-04-01 The Scripps Research Institute Method for producing human antibodies in a non-human animal, and animals therefor

Also Published As

Publication number Publication date
EP0539970A3 (en) 1994-05-25
US5681729A (en) 1997-10-28
DE69229254D1 (de) 1999-07-01
US5869268A (en) 1999-02-09
EP0539970A2 (de) 1993-05-05
EP0539970B1 (de) 1999-05-26

Similar Documents

Publication Publication Date Title
DE69229254D1 (de) Verfahren zur Herstellung von menschlichen Lymphozyten und menschlichen Antikörpern; und so hergestellte Antikörper
DE69322094D1 (de) Heterogene membrane und verfahren zur herstellung
DE69126762D1 (de) Biologisches Verfahren zur Herstellung von Alpha-Hydroxyamid und Alpha-Hydroxysäure
DE68912909D1 (de) Verfahren zur Herstellung von Nitrilen und Oxiden.
DE69310669D1 (de) Prozess und Vorrichtung zur Herstellung von Allylchlorid
DE68927949D1 (de) 3,9-Diphosphaspiroundecane und Verfahren zur Herstellung von 3,9-Diphosphaspiroundecanen
DE69311817D1 (de) Verfahren zur Herstellung von Kohle-Kohle-Verbund-Vorformen und Kohle-Kohle-Verbund
ATA111789A (de) Humaner monoklonaler antikörper und hybridom zur herstellung desselben
DE68928619D1 (de) Verfahren zur Herstellung von mono-N-alkylierten Polyazamacrocyclen
DE69220113T2 (de) Verfahren zur Herstellung von menschlichem Serum Albumin
DE59606485D1 (de) Verfahren zur Herstellung von Poly-o-hydroxyamiden und Poly-o-mercaptoamiden
DE69214750D1 (de) Verfahren zur Herstellung von Tribromstyrol und beta-Bromethyltribrombenzol
DE69028820D1 (de) Vorrichtung zur Herstellung von Kunststoffbeuteln und entsprechende Herstellungsmethode
DE59606489D1 (de) Verfahren zur Herstellung von Poly-o-hydroxyamiden und Poly-o-mercaptoamiden
DE69508151D1 (de) Verfahren zur Herstellung von Verbundfolie und Verbundfolie
DE59606657D1 (de) Verfahren zur Herstellung von Poly-o-hydroxyamiden und Poly-o-mercaptoamiden
DE69424503D1 (de) Verfahren zur Herstellung von Dimethylchlorsilan und Triorganochlorsilan
DE69207051D1 (de) Substituierte Acetoxyazetidinonderivate und Verfahren zur Herstellung von 4-Acyloxyazetidinonderivate
DE59606488D1 (de) Verfahren zur Herstellung von Poly-o-hydroxyamiden und Poly-o-mercaptoamiden
DE68929433T2 (de) Verfahren zur Herstellung von JFET-Transistoren und Kondensatoren
DE68913779D1 (de) D-Amidase und Verfahren zur Herstellung von D-alpha-Alanin und/oder L-alpha-Alaninamid.
DE68927119T2 (de) Verfahren zur Herstellung von 4-Hydroxypyrimidin
DE59206187D1 (de) Verfahren zur Herstellung von 4-Alkylsulfonyl-1-alkyl-2-chlorbenzolen und Zwischenprodukte
DE59607034D1 (de) Verfahren zur Herstellung von Poly-o-hydroxyamiden und Poly-o-mercaptoamiden
DE4294717T1 (de) Verfahren zur Herstellung von medizinischen Beuteln

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee